ONCONETIX INC (ONCO) Stock Overview
USA - NASDAQ:ONCO - US68237Q2030 - Common Stock
ONCO Key Statistics, Chart & Performance
The current stock price of ONCO is 3.58 USD. In the past month the price increased by 4.13%. In the past year, price decreased by -98.92%.
ONCO Latest News, Press Relases and Analysis
ONCO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.46 | 401.40B | ||
| AMGN | AMGEN INC | 13.27 | 155.77B | ||
| GILD | GILEAD SCIENCES INC | 15.55 | 149.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.76 | 61.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.15B | ||
| ARGX | ARGENX SE - ADR | 90.02 | 51.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.67B | ||
| INSM | INSMED INC | N/A | 34.50B | ||
| NTRA | NATERA INC | N/A | 26.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.37B | ||
| BIIB | BIOGEN INC | 9.36 | 21.97B |
Related stock screener links
About ONCO
Company Profile
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Company Info
ONCONETIX INC
201 E. Fifth Street, Suite 1900
Cincinnati OHIO US
Employees: 5
Phone: 15136204101
ONCONETIX INC / ONCO FAQ
What does ONCONETIX INC do?
Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Can you provide the latest stock price for ONCONETIX INC?
The current stock price of ONCO is 3.58 USD. The price increased by 1.42% in the last trading session.
What is the dividend status of ONCONETIX INC?
ONCO does not pay a dividend.
How is the ChartMill rating for ONCONETIX INC?
ONCO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of ONCO stock?
ONCONETIX INC (ONCO) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for ONCO stock?
ONCONETIX INC (ONCO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-593.67).
What is the market capitalization of ONCO stock?
ONCONETIX INC (ONCO) has a market capitalization of 5.55M USD. This makes ONCO a Nano Cap stock.
ONCO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ONCO. When comparing the yearly performance of all stocks, ONCO is a bad performer in the overall market: 97.85% of all stocks are doing better.
ONCO Financial Highlights
Over the last trailing twelve months ONCO reported a non-GAAP Earnings per Share(EPS) of -593.67. The EPS increased by 93.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -240.02% | ||
| ROE | -722.3% | ||
| Debt/Equity | 1.37 |